Buy Mabtas : Rituximab 100 mg/10 ml Injection Online

Mabtas: Rituximab 100 mg/10 ml Injection is a monoclonal antibody used to treat various kinds of cancer and autoimmune diseases. The composition of Mabtas contains the active ingredient rituximab, which is a chimeric monoclonal antibody produced from mouse and human proteins.

Uses:

Mabtas is primarily used to treat Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. It is also used to treat certain autoimmune diseases such as systemic lupus erythematosus and pemphigus vulgaris.

Usage and Dosage:

Mabtas is administered via intravenous infusion. The dosage and duration of therapy vary depending on the indication, patient’s age, and overall health status. The recommended dose for Non-Hodgkin’s lymphoma and chronic lymphocytic leukemia is 375 mg/m2, administered in combination with chemotherapy. For rheumatoid arthritis, the recommended dose is 1000 mg on days 1 and 15 of therapy.

Storage Conditions:

Mabtas should be stored in a refrigerator between 2-8°C. The solution should not be frozen, shaken, or exposed to direct sunlight.

Mechanism of Action:

Mabtas works by targeting and destroying cancerous and abnormal cells in the body. It binds to a protein called CD20, which is found on the surface of B-cells, and triggers their destruction through various mechanisms.

Contraindications:

Mabtas should not be used in patients who have a history of severe allergic reactions to rituximab or any of its components. It should also be avoided in patients with active infections, severe immunodeficiency, or a history of hepatitis B.

Interactions:

Mabtas may interact with other medications such as live vaccines, immunosuppressive drugs, and corticosteroids. Therefore, patients should inform their doctor of all medications they are taking or planning to take.

Adverse Reactions:

Mabtas may cause several adverse reactions, including infusion-related reactions, fever, headaches, chills, nausea, vomiting, and respiratory issues. Additionally, it may increase the risk of infections, malignancies, and progressive multifocal leukoencephalopathy.

In conclusion, Mabtas: Rituximab 100 mg/10 ml Injection is an effective treatment option for various cancers and autoimmune diseases. However, it should only be used with proper medical supervision and monitored for adverse reactions. Patients should inform their doctors of any pre-existing conditions or medications they are taking before starting Mabtas therapy.